209.64USD-4.09%Mkt Cap: —P/E: —1d ago
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value11.26B $
Revenue (TTM)776.57M $
Gross Profit724.04M $
Net Income (TTM)-191.64M $
Revenue/Share15.25 USD
Last Price209.64 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.3K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS05464T1043
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-65.12
EV/Revenue14.50
P/S—
P/B135.07
EPS (TTM)-3.72
EPS (Forward)—
52W Range
209.640% of range221.85
52W High221.85 USD
52W Low209.64 USD
Profitability
Gross Margin93.24%
Oper. Margin-23.42%
EBITDA Margin-22.27%
Profit Margin-24.68%
ROE-245.10%
ROA-16.31%
Growth
Revenue Growth45.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-71.26M $
CapEx (TTM)—
FCF Margin-0.59%
FCF Yield—
Net Debt-95.16M $
Net Debt/EBITDA0.55
Balance Sheet
Debt/Equity269.73
Current Ratio1.43
Quick Ratio1.30
Book Value/Sh1.593 USD
Cash/Share6.106 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.29.81M
Float44.46M
Insiders15.08%
Institutions74.58%
Technical
SMA 5085.35 (+145.6%)
SMA 20075.30 (+178.4%)
Beta0.73
S&P 52W Chg20.80%
Avg Vol (30d)375
Avg Vol (10d)357
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—